Regeneron, a biotechnology company, teamed up with Binghamton University’s Neurodiversity Club this week to host a panel ...

This was the stock's fourth consecutive day of losses.

Summit Therapeutics' ivonescimab poised for FDA approval, with the potential to disrupt the oncology market. Read more on ...

Genomics is on the brink of revolutionizing healthcare with breakthroughs that could redefine treatment and diagnosis. As ...

Stocks to Look After. In this article, we are going to take a look at where Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) ...

Shares of Regeneron Pharmaceuticals Inc. REGN shed 0.55% to $1,146.75 Tuesday, on what proved to be an all-around mixed ...

In the Phase I trial, the duration of response to Regeneron's combination therapy continued beyond two years in melanoma ...

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research ...

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Regeneron (REGN – Research Report) and keeping the price target at ...

Regeneron is back with long-term follow-up for its LAG-3 inhibitor and PD-1 inhibitor combo in advanced melanoma, phase 1 ...

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved blockbuster drug Dupixent (dupilumab) for the indication of chronic rhinosinusitis with nasal polyps (CRSwNP) for a broader ...

Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with an inflammatory skin disease in a ...